drugset / Trial / NCT03313661
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluation of the glycemic efficacy of cabergoline on diabetic patients
Timeline
- Start
- 2017-10-14
- Primary completion
- 2020-10
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabergoline | Small molecule | 0.5 mg | — |
| Comparator | Gliclazide | Small molecule | 60 mg | — |
| Comparator | Gliclazide | Small molecule | 120 mg | — |